Bitmine Is Trading Below Liquidation Value!
1 extracted signal · 0 resolved · 1 still active
The Patient Investor30 Jun 2026, 18:13 UTC
AI-generated source summary
The analysis focuses on the stock ticker BMNR, suggesting a bullish outlook. The current price is $13.80, with a target price of $25.00. The failure bound is set at $10.00, indicating that a drop below this level would invalidate the bullish thesis. The timeframe for this analysis is daily (1D). The stock has been in a bearish trend, but the analyst believes it is undervalued and poised for a rebound. The target of $25.00 represents a significant upside potential based on the ETH/BTC ratio analysis presented, which implies an ETH fair value of $12k to $22k. At an ETH price of $100,000 and an 8-year average ETH/BTC ratio of 0.0479, the implied ETH value is $4,790. If the ETH/BTC ratio reaches its high of 0.2500, the implied ETH value could be $25,000. The analyst also mentions a $4 billion share repurchase program as a positive fundamental factor. The company's financial health, indicated by its lack of debt and its ability to cover dividend obligations, is also seen as supportive.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Signals in this source
More Prediction Case Files from The Patient Investor
Why I Don't Own Google Stock & When I'm Buying
The CHEAPEST Quality Stock In The Stock Market!
Intuitive Surgical Stock Analysis! Risks & Upside Potential
There Is NO AI BUBBLE! I’m Buying Every Dip
2 Stocks I'm Buying In The Next 2 Weeks
Netflix Stock Is FINALLY A Buy!
The Patient Investor
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
